ENहिन्दी soon
Home/India/Answers/Mounjaro in India
INIndia Medicines

Is Mounjaro available in India?

GLP Guidebook teamUpdated 5 Oct 202613 sourcesWritten from published sources
The short answer

Yes. Eli Lilly launched Mounjaro (tirzepatide) in India on 20 March 2025. It is approved for type 2 diabetes and for weight management in some adults. It is prescription-only, sold as a weekly vial or a monthly KwikPen. Cipla sells Lilly's tirzepatide as a second brand, Yurpeak. On 5 October 2026 the 2.5 mg KwikPen's printed MRP was ₹13,125.

Before you go further
  • GLP‑1 medicines, Mounjaro included, are prescription-only in India, not sold over the counter.9
  • A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.9 For tirzepatide, CDSCO expert-committee minutes from April 2023 set a similar condition: sold on the prescription of an endocrinologist or internal-medicine specialist. We found no rule covering every brand.13
  • The risks are in Guide 5: Side effects and risks.
  • Nothing here promises any result, and nothing here is for sale.

When did Mounjaro launch in India?

Eli Lilly launched Mounjaro in India on 20 March 2025, as single-dose vials of 2.5 mg and 5 mg.

The regulator is the Central Drugs Standard Control Organisation (CDSCO). A CDSCO expert committee first recommended tirzepatide in April 2023.13 In June 2024 it recommended adding weight management. Its condition: Lilly runs a Phase IV trial.11 Lilly launched the vials after CDSCO gave its marketing approval.1,2 CDSCO then cleared a pen version, the KwikPen, in June 2025.3 Lilly launched the pen in August 2025, in 6 strengths from 2.5 mg to 15 mg.3

What is Mounjaro approved for in India?

Lilly says Mounjaro is approved in India for 2 uses: type 2 diabetes, and long-term weight management in some adults.

For diabetes, it is used with diet and exercise to control blood sugar.2 For weight, it is used with a lower-calorie diet and more activity. That covers adults with a BMI of 30 or more, or 27 or more with at least 1 weight-related condition.2 We found no public Indian label, so these come from Lilly's launch statement.

Those BMI numbers belong to the medicine's approval. India's own definition of obesity starts lower, at a BMI of 25.10 Guide 1 explains the Indian cut-offs. Meeting a number does not settle anything; a doctor decides.

What is the difference between the Mounjaro vial and the KwikPen?

A Mounjaro vial in India holds 1 weekly dose; a KwikPen holds 4, so 1 pen lasts about a month.

The vials in India are single-dose, and Lilly launched them in 2.5 mg and 5 mg only.2,3 The KwikPen comes in 6 strengths, and its price covers a one-month supply.3 The US label says each KwikPen contains 4 doses.5

What is Yurpeak?

Yurpeak is Lilly's tirzepatide, sold by Cipla since 10 December 2025 at the same price as Mounjaro.

Cipla calls it the second brand of Lilly's tirzepatide in India, and Lilly makes it. It has the same 2 approved uses, comes as a KwikPen in 6 strengths, and needs a prescription.4

What does Mounjaro cost in India?

On 5 October 2026, the 2.5 mg Mounjaro KwikPen had a printed MRP of ₹13,125 for 4 weekly doses.

Printed MRPs run from ₹13,125 (2.5 mg) to ₹25,781 (12.5 mg and 15 mg) per pen.7,8 At launch, the KwikPen cost ₹14,000 a month for 2.5 mg, rising to ₹27,500 for 12.5 mg and 15 mg.3 The vials launched at ₹3,500 (2.5 mg) and ₹4,375 (5 mg).1

GST on most medicines fell from 12% to 5% on 22 September 2025.6 The national drug-price regulator (NPPA) told makers to revise MRPs from that date.12 The new MRPs are the launch MRPs with the lower tax worked in (× 105/112). That is our arithmetic; we found no Lilly statement. A year at 5 mg is 13 pens, about ₹2.13 lakh. Every strength will be in What is the MRP of Mounjaro in India?.

Work out a full year's cost

Medicine, doctor visits and tests, in ₹. Free, no sign-up.

Open the calculator
RisksThe risks, in brief
  • Stomach effects are common. In the US label's diabetes trials, 12% to 18% felt sick (nausea) on Mounjaro, vs 4% on a dummy injection.5
  • Dehydration from vomiting or diarrhoea can harm the kidneys.5
  • A swollen pancreas (pancreatitis) and gallbladder problems are label warnings. Gallbladder problems hit 0.6% on Mounjaro vs 0% on a dummy.5
  • Low blood sugar (hypos) is more likely with insulin or a sulfonylurea.5
  • Thyroid C-cell tumour warning. The US label rules it out with a personal or family history of a rare thyroid cancer (MTC) or MEN 2; tell your doctor if this applies.5
  • Pregnancy and the pill. Animal studies suggest it may harm an unborn baby. The label says to use it in pregnancy only if the benefit justifies that risk. It can make the contraceptive pill less reliable. The label advises a non-pill or barrier method for 4 weeks after starting and after each dose rise.5
Full detail in Guide 5: Side effects and risks →

Read the full picture

Related questions

What is the MRP of Mounjaro in India? Is there a generic Mounjaro (tirzepatide) in India? What is tirzepatide? Do you need a prescription for GLP-1 medicines in India?
Did this answer your question?

Sources

  1. Business Standard (Sohini Das, with Reuters). Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India, 20 Mar 2025. business-standard.com
  2. Indian Pharma Post. Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes (Lilly India launch statement), 24 Mar 2025. indianpharmapost.com
  3. Business Standard (citing Reuters). Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity, 13 Aug 2025. business-standard.com
  4. Cipla Ltd. Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes. Press release, 10 Dec 2025. cipla.com (PDF)
  5. Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised 08/2026. US label, not the Indian one: we found no public Indian label. Boxed warning; sections 3, 4, 5.2, 5.3, 5.5, 5.8, 6.1 (Table 2), 8.1, 8.3. pi.lilly.com
  6. Press Information Bureau, Ministry of Finance. Recommendations of the 56th meeting of the GST Council, 3 Sep 2025 ("Reduction of GST on all other drugs and medicines from 12% to 5%"; goods from 22 Sep 2025). gstcouncil.gov.in (PDF)
  7. Tata 1mg, Medkart and PharmEasy product listings, printed MRP of the Mounjaro 2.5 mg KwikPen (₹13,125; marketer Eli Lilly and Company India). Pharmacy listings, used only for the printed MRP, checked 5 Oct 2026.
  8. PharmEasy, MrMed and Tata 1mg product listings, printed MRPs of Mounjaro KwikPens: 5 mg ₹16,406 (MrMed ₹16,406.25); 12.5 mg and 15 mg ₹25,781 (MrMed ₹25,781.25). Pharmacy listings, used only for the printed MRP, checked 5–5 Oct 2026.
  9. PIB Research (Government of India). GLP-1 Drugs: Use, Risks, and Regulation. Backgrounder, 1 Apr 2026. pib.gov.in (PDF)
  10. Misra A et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians. J Assoc Physicians India 2009;57:163-70. PMID 19582986
  11. CDSCO. Recommendations of the SEC (Endocrinology & Metabolism), 12th/24 meeting, 19 Jun 2024: tirzepatide pens and vials recommended for chronic weight management "subject to condition that firm should conduct Phase-IV clinical trial". cdsco.gov.in (PDF) · archived copy
  12. NPPA Office Memorandum F. No 12(24)/2021/DP/NPPA/Div.II(Vol.II)-Part(1), 12 Sep 2025: revise MRPs from 22 Sep 2025 in line with the GST cut. Summary by CliniExperts. cliniexperts.com
  13. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 100th meeting, 20–21 Apr 2023, item 1 (tirzepatide, Eli Lilly). Committee minutes, not the final permission. cdsco.gov.in (PDF) · archived copy

Last checked 5 Oct 2026 · Next review due 6 Apr 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above. We checked each MRP on 5 Oct 2026 and used only printed MRPs, never a seller's discount price. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write